Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Abatacept Appears Safe for RA Patients with COPD

Key clinical point: Abatacept doesn’t appear to exacerbate COPD in patients with rheumatoid arthritis.

Major finding: Risks for COPD exacerbation, flu, bronchitis, and pneumonia were not significantly elevated versus those with other biologic DMARDs.

Study details: The MarketScan database review comprised 4,634 patients.

Disclosures: Dr. Suissa disclosed relationships with AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, and Novartis.

Citation:

Suissa S et al. Semin Arthritis Rheum. 2019 Mar 16. doi: 10.1016j.semarthrit.2019.03.007.

Must Reads in COPD

LABA-LAMA vs LABA-ICS in Treatment of COPD, Chest; ePub 2019 Mar 26; Suissa, et al

Follow-Up After Discharge in COPD Readmissions, Chronic Obstr Pulm Dis; ePub 2019 Mar; Budde, et al

CAP Burden in Patients with COPD, Chronic Obstr Pulm Dis; ePub 2019 Mar; Pasquale, et al

COPD and Angiographically Diagnosed CAD, COPD: J Chron Obstr Pulm Dis; ePub 2019 Mar 22; Hong, et al

Methodologies to Identify Patients with AECOPD, Int J Chron Obstruct Pulmon Dis; 2019 Mar 22; Shah, et al